2,418
Views
0
CrossRef citations to date
0
Altmetric
Original Articles: Clinical Oncology

2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial

ORCID Icon, , , , , , , & show all
Pages 963-971 | Received 16 Apr 2022, Accepted 01 Jul 2022, Published online: 18 Jul 2022